SCHEMBL7513360

SCHEMBL7513360

CCOC(=O)c1cn(Cc2c(F)cccc2F)c2sc(-c3ccccc3)c(CBr)c2c1=O

nearest known ligand 0.69

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 20/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7498273 0.90 GNRHR (0.67) GNRHR
SCHEMBL7504660 0.89 GNRHR (0.60) GNRHR
SCHEMBL7525348 0.85 GNRHR (0.64) GNRHR
SCHEMBL7490308 0.83 GNRHR (0.63) GNRHR
SCHEMBL7495737 0.82 GNRHR (0.73) GNRHR
SCHEMBL7011581 0.82 GNRHR (1.00) GNRHR
Hydrochloric Acid SCHEMBL7500013 0.81 GNRHR (0.98) GNRHR
SCHEMBL7492238 0.79 GNRHR (0.63) GNRHR
SCHEMBL7014768 0.79 GNRHR (0.82) GNRHR
SCHEMBL7493954 0.79 GNRHR (0.59) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020198384-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-12-26 US claimed
US-20020019529-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-02-14 US claimed
EP-1004585-A1 THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH Takeda Chemical Industries, Ltd. (JP) 2000-05-31 EP claimed
US-20020198384-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-12-26 US disclosed
US-6437132-B2 INHIBITOR OF GONADOTROPIN RELEASING HORMONE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-20 US disclosed
EP-1194429-A1 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-10 EP disclosed
US-20020019529-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-02-14 US disclosed
US-6313301-B1 CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-11-06 US disclosed
WO-2000078768-A1 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-12-28 WO disclosed
EP-1004585-A1 THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH Takeda Chemical Industries, Ltd. (JP) 2000-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198384-A1 Thienopyridine derivatives, their intermediates and production thereof GNRHR, KISS1R, CYP19A1 GNRHR 1/4885
US-20020019529-A1 Thienopyridine derivatives, their intermediates and production thereof GNRHR, KISS1R, CYP19A1 GNRHR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.